[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,154,0,25,[9,45,76,107,133,163,184,204,229,251,278,304,331,352,376,404,429,459,483,511,540,563,589,607,630],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100524545","phase-4-effect-of-empagliflozin-on-podocyte-specific-proteins-in-african-american-veterans-with-ndkd-100524545",false,"NCT06110130","Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD","Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Non-Diabetic Chronic Kidney Disease","EMPA CKD","Inclusion Criteria:\n\n1. African American veterans\n2. Age \\> 18 years\n3. eGFR ≥20-59 mL\u002Fmin\u002F1.73 m2 by the CKD-EPI equation, with or without any degree of albuminuria OR\n4. eGFR 60-89, with UACR of ≥30mg\u002Fg\n5. BMI = 18-39.9\n6. Blood pressure controlled to ≤140\u002F90\n7. Subjects without diabetes: will be screened using routine glucose level test: of less than 126 fasting glucose or less than 200mg\u002Fdl of random or post glucose blood glucose level in standard of care laboratory workup.\n8. Ability to provide informed consent before any trial related activities are conducted.\n\nExclusion Criteria:\n\n1. Diagnosed with Type 1 or Type 2 Diabetes Mellitus\n2. Any prescribed diabetes medication for patients, such as GLP1RA, SGLT2is, and sulphonylureas\n3. If a patient is on statin, need to be on a stable dose for a month.\n4. Biopsy proven diagnosis of glomerular disease\u002Fglomerulonephritis\n5. Active smokers,\n6. Active skin wounds undergoing treatment or recent surgery within 1 month (due to possible aberrations in glycemic control)\n7. Women who are pregnant, planning to become pregnant, nursing mothers, women of childbearing potential not using birth control measure\n8. Hypersensitivity to empagliflozin or any of the excipients in Jardiance, reactions such as angioedema\n9. Patients on dialysis\n10. eGFR less than 20 mL\u002Fmin\u002F1.73 m2 by the CKD-EPI equation\n11. Planned surgery or planned hospital admission within 5 months of participation in the study\n12. At the discretion of PI to ensure health, safety, and well-being of the veteran, participation in this study may be stopped (please see withdrawal criteria)\n13. Patients with prior history of diagnosis of heart failure with documented EF of less than 50.\n14. Proven diagnosis of Polycystic Kidney Disease.","ALL","19 Years","90 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Primary Objective:\n\nTo study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease (NDKD), on empagliflozin therapy.\n\nPrimary Endpoint: We will assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.\n\nSecondary Objectives:\n\n1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin\u002Fcreatinine ratio (ACR) and estimated GFR.\n2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and arterial stiffness measures with urine exosome-based podocyte protein estimation \\[11, 27-29\\].\n3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC)",[29],"Chronic Kidney Diseases",[31],"Non-diabetic","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2024-02-02",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"Washington D.C. Veterans Affairs Medical Center","FED",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100549182","early-phase-1-feasibility-trial-of-sodium-glucose-cotransporter-2-inhibitors-in-pediatric-chronic-kidney-disease-100549182","NCT06430684","Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease","SGLT2I-IN-KIDS","Inclusion Criteria:\n\n* Stage 3-4 CKD; estimated GFR using CKiD U25-creatinine equation 20-60mL\u002Fmin\u002F1.73m2\n\nExclusion Criteria:\n\n* Heart Disease\n* Diabetes\n* Pregnancy\n* Recipient of solid organ transplant\n* history of chemotherapy or stem cell transplant\n* moderate to severe persistent asthma\n* liver disease\n* class 2 or greater obesity\n* inability to follow study procedures due to cognitive impairment\n* obstructive uropathy or requirement for intermittent urinary catheterization\n* systolic blood pressure \\\u003C100mgHg\n* orthostatic hypotension\n* current use of an SGLT2i\n* anticipated need for titration of anti-hypertensives within 3 months\n* active use of any immunosuppressive medications\n* lack of clearance by primary nephrologist for participation","12 Years","25 Years",{"count":55,"type":23},40,[57],"EARLY_PHASE1","The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are:\n\n1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)?\n2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests?\n\nParticipants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care.\n\nStudy Procedures Include\n\n* For participants randomly selected for treatment, take empagliflozin once daily for 3 months\n* Phone calls with researchers every 2 weeks for check-ins\n* For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests\n* All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests",[29,60],"Pediatric Kidney Disease",[62,63,64,65,66],"Sodium Glucose Co-Transporter 2 Inhibitor","SGLT2i","Pediatric CKD","Feasibility Study","Clinical Trial","2026-08-18",{"date":33,"type":36},{"date":70,"type":36},"2024-08-23",{"date":72,"type":23},"2026-11-01",{"name":74,"class":75},"Ann & Robert H Lurie Children's Hospital of Chicago","OTHER",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100652155","negative-pressure-wound-therapy-devices-in-total-knee-arthroplasty-100652155","NCT07770633","Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty","Randomized Controlled Clinical Trial for Closed Incision Negative Pressure Wound Therapy (NPWT) Devices in Total Knee Arthroplasty (TKA)","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergoing primary total knee arthroplasty\n* Able to understand the study, provide informed consent, and participate in study procedures\n\nMeet at least one of the following co-morbidities:\n\n* BMI ≥35\n* Diabetes\n* Prior surgical incision(s) in the operative area\n* Chronic kidney disease\n\nExclusion Criteria:\n\n* Prisoners\n* Pregnant women\n* Patients who indicate they may not comply with post-operative instructions\n* Patients with active bleeding",true,"18 Years",{"count":86,"type":23},300,[88],"NA","This study is a single-center, prospective, randomized, open-label clinical trial evaluating three commercially available closed-incision negative pressure wound therapy (ciNPWT) devices: NPseal, PICO, and Prevena, in adult patients undergoing primary total knee arthroplasty (TKA) who meet predefined high-risk criteria for wound complications.\n\nA total of approximately 300 participants will be enrolled and randomized in a 1:1:1 fashion to receive one of the three study dressings applied over the closed surgical incision at the end of the procedure. All participants will otherwise receive standard perioperative and postoperative care. The primary follow-up period will extend through 90 days after surgery.\n\nThe primary objective is to compare the incidence of 90-day surgical site complications, including superficial infection, wound dehiscence, seroma, and hematoma, across the three dressing groups. Secondary objectives include evaluation of device usability, patient experience, and device-related issues (such as loss of seal, alarms, tubing or pump problems, fluid saturation, and premature dressing changes), as well as assessment of the interaction between skin closure method and device performance.\n\nResearch-specific activities are limited to eligibility confirmation, informed consent, randomization, administration of a brief postoperative patient survey at approximately postoperative day 7 and\u002For dressing removal, provider assessment of the dressing at removal, and collection of clinical outcomes from the medical record. No additional blood draws, imaging, or invasive procedures are required for participation.\n\nThis study is designed to address a gap in the literature by providing head-to-head comparative data on commonly used ciNPWT systems in a high-risk primary TKA population, with the goal of informing postoperative wound management strategies in clinical practice.",[91,92,93,29,94],"Wound Surgical","Diabetes","Obesity","Smoking",[96,97],"Total Knee Arthroplasty","Total Knee Replacement","NOT_YET_RECRUITING","2026-08-17",{"date":67,"type":36},{"date":102,"type":23},"2026-09-01",{"date":104,"type":23},"2030-12",{"name":106,"class":75},"The Cleveland Clinic",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100648721","designing-and-implementing-a-safety-net-surveillance-program-for-high-risk-ckd-100648721","NCT07724288","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD (CKD Safety Net)","CKD Safety-Net","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Resident of Manitoba \u002F has Manitoba Health coverage\n* Either:\n* 2 eGFR \\\u003C15 mL\u002Fmin\u002F1.73m2 tests within a 2-year timeframe or\n* A greater than 10% 2-year kidney failure risk (at 2 separate timepoints within a 2-year timeframe) - using the 4-variable or 3-variable 2-year Kidney Failure Risk Equation (KFRE)\n\nExclusion Criteria:\n\n* A previous billing claim from a nephrologist\n* Receiving palliative care within 3 months of randomization\n* Previous history of dialysis and\u002For kidney transplantation",{"count":116,"type":23},972,[88],"The objective of this initiative is to develop and evaluate a risk-based, provincial public health screening program for chronic kidney disease (CKD) that provides proactive care for adults at high-risk of kidney failure who have not previously been referred to a nephrologist, through risk stratification, triage, education, and follow-up.\n\nOverall, we aim to demonstrate that an integrated risk-based provincial public health screening program for CKD is feasible, and improves identification of high-risk individuals, subsequently creating a model of care that can be adopted by other jurisdictions.",[29],[121,122,123,124],"Chronic Kidney Disease","Kidney Diseases","Access to care","Secondary Prevention","2026-08-12",{"date":99,"type":36},{"date":128,"type":23},"2026-08",{"date":130,"type":23},"2028-03",{"name":132,"class":75},"University of Manitoba",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":162},"100504305","registry-of-gore-acuseal-vascular-graft-in-dialysis-access-100504305","NCT05846581","Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access","Observational Prospective Post-Market Clinical Follow-Up (PMCF) Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access","AVG22-09","Inclusion Criteria:\n\n1. The patient requires the creation of vascular access for hemodialysis secondary to a diagnosis of End-Stage Renal Disease and intends to use GORE® ACUSEAL Vascular Graft device for arteriovenous (AV) access.\n2. Age ≥18 years at time of Informed Consent Form (ICF) signature.\n3. Willingness of the patient to adhere to institutional standard of care follow-up.\n4. Informed Consent Form (ICF) is signed by the patient.\n5. The patient is currently on hemodialysis or intended to begin hemodialysis immediately following placement of the GORE® ACUSEAL Vascular Graft device or up to 30 days following placement of the device.\n6. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.\n\nExclusion Criteria:\n\n1. The patient currently has a known or suspected systemic infection.\n2. The patient is pregnant or breastfeeding.\n3. The patient had a separate interventional or surgical vascular procedure within the study limb within 30 days prior to treatment with the GORE® ACUSEAL Vascular Graft device.\n4. The patient had a previous documented (via imaging technique) and unsuccessfully treated ipsilateral central venous stenosis.\n5. The patient is currently taking maintenance corticosteroids and immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (\\> 10 mg), cyclosporine, tacrolimus, or cyclophosphamide.\n6. The patient has a known hypercoagulability or bleeding disorder.\n7. The patient has had a previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known sensitivity to Heparin.\n8. The patient is enrolled in an investigational study.\n9. The patient has been previously enrolled in this registry.\n10. The patient is currently being considered for a live donor kidney transplant (living donor either related or unrelated to patient).\n11. The patient has life expectancy less than 2 years.",{"count":142,"type":23},72,"24 Months","OBSERVATIONAL","The goal of this observational study is to evaluate safety and performance of GORE® ACUSEAL Vascular Graft for the treatment of CKD in patients with ESRD in hemodialysis. The main questions it aims to answer are:\n\n* Safety: Freedom from device-related infection adverse events at 24 months from device implant\n* Performance: Secondary patency at 24 months from device implant.\n\nParticipants, after informed consent is obtained, will be implanted with GORE® ACUSEAL Vascular Graft and followed for 24 months in standard of care, to evaluate safety and performance of the device.",[29,147],"End Stage Renal Disease on Dialysis",[149,29,150,151,152],"Post-Market Clinical Follow-Up","End Stage Renal Disease","Hemodialysis","vascular graft",{"date":154,"type":36},"2026-08-13",{"date":156,"type":36},"2024-01-12",{"date":158,"type":23},"2027-10-27",{"name":160,"class":161},"W.L.Gore & Associates","INDUSTRY",4,{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100424092","real-world-evidence-clinical-utility-study-of-kidneyintelx-100424092","NCT04802395","Real World Evidence Clinical Utility Study of KidneyIntelX","Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease","Inclusion Criteria:\n\n* Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.\n\nExclusion Criteria:\n\n* Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population.\n* Patients with eGFR \\\u003C30 or ≥ 60 ml\u002Fmin\u002F1.73m2 without albuminuria.\n* Patients with ESRD or on renal recovery treatments at time of enrollment.\n* Patients who are pregnant at the time of enrollment.\n* Patients who are currently hospitalized.\n* Patients without minimum 6 month pre-baseline KidneyIntelX medical history.\n* Patients who are currently on Enbrel.","23 Years",{"count":172,"type":23},10000,"The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.",[29,175],"Diabetic Kidney Disease","2026-08-11",{"date":154,"type":36},{"date":179,"type":36},"2021-03-02",{"date":181,"type":23},"2026-12-01",{"name":183,"class":161},"Renalytix AI, Inc.",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":24,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":44},"100626076","pragmatic-trial-of-messaging-to-providers-about-treatment-of-chronic-kidney-disease-100626076","NCT07430930","Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease","PROMPT-CKD","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years\n2. Diagnosed with CKD defined by an eGFR ≤60 mL\u002Fmin\u002F1.732 on two occasions at least ≥3 months apart with most recent being ≤60 or eGFR 60-90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg or eGFR \\>90 mL\u002Fmin\u002F1.73m2 with an uACR ≥30 mg\u002Fg.\n3. Eligible to receive at least 1 of the following CKD GDMT: ACEi\u002FARB, SGLT2i, MRA or GLP-1 RA based on the following criteria.\n4. To receive an ACEi\u002FARB: eGFR ≥15 ml\u002Fmin\u002F1.732 and have diagnosis of hypertension based on ICD10 code or proteinuria (uACR ≥30 mg\u002Fg).\n5. To receive an SGLT2i: have heart failure (defined by ICD10 code); or T2D; or uACR ≥200 mg\u002Fg; or eGFR ≥20 ml\u002Fmin\u002F1.732.\n6. To receive an MRA: ns-MRA: have an eGFR ≥25 ml\u002Fmin\u002F1.732, diagnosis of T2D, normal serum potassium (≤4.8 mmol\u002FL) and albuminuria (\\>30 mg\u002Fg). s-MRA: have an eGFR ≥45 ml\u002Fmin\u002F1.732 and heart failure, hyperaldosteronism, or refractory hypertension.\n7. To receive a GLP-1 RA: have T2D.\n8. Ability to take oral medication.\n\nExclusion Criteria:\n\n1. Allergy to the GDMT for which the patient is eligible\n2. End-stage kidney disease\n3. CKD stage 5 (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2)\n4. Glomerulonephritis (by ICD-10 code)\n5. Polycystic kidney disease (by ICD-10 code)\n6. History of kidney transplant\n7. End-stage heart failure\n8. Eligible to receive ACEi\u002FARB but having blood pressure \\\u003C110\u002F70 mmHg or have known renal artery stenosis\n9. Eligible to receive SGLT2i but pregnant or breastfeeding, type 1 DM, history of euglycemic diabetic ketoacidosis or Fournier's gangrene based on ICD10 code.\n10. Eligible to receive MRA but serum potassium ≥5 mmol\u002FL, have office SBP \\\u003C100 mmHg, adrenal insufficiency based on ICD10 code or concomitant treatment with CYP3A4 inhibitors (Strong: grapefruit, grapefruit juice, itraconazole. Moderate: erythromycin. Weak: amiodarone).\n11. Eligible to receive GLP-1 RA but pregnant; or found to have personal history of pancreatitis; or personal or family history of medullary thyroid cancer or MEN type 2 based on ICD10 code or gastroparesis based on ICD10 code.\n12. Opted out of EHR-based research.",{"count":192,"type":23},1000,[88],"This study is a cluster-randomized clinical trial to evaluate whether a tailored, user-centered, clinical decision support (CDS) tool can positively influence prescriber behavior and increase prescription of guideline-directed medical therapy (GDMT) among patients with Chronic Kidney Disease (CKD) across a single healthcare center.",[29],"2026-08-07",{"date":176,"type":36},{"date":199,"type":23},"2026-09",{"date":201,"type":23},"2028-09",{"name":203,"class":75},"Yale University",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":44},"100598663","phase-4-effect-of-empagliflozin-in-patients-with-egfr-between-10-and-20-mlmin173m2-100598663","NCT07074418","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2","Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml\u002FMin\u002F1.73m2 - EMPA [10-20]","EMPA[10-20]","Inclusion Criteria:\n\n* type 2 diabetics,\n* age between 18 and 80 years,\n* RAS blockade at maximal tolerated dosage for 1 month,\n* eGFR (CKD-EPI) between 10 and 20 ml\u002Fmin\u002F1.73m2,\n* UACR \\> 300mg\u002Fg creatinine and UPCR \\> 500mg\u002Fg creatinine,\n* office systolic blood pressure \\> 110 mmHg,\n* stable dosage of antihypertensive drugs and diuretics for 1 month.\n\nExclusion Criteria:\n\n* any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,\n* history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,\n* participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,\n* known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,\n* judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,\n* no social insurance,\n* unwilling to give informed consent, vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).","80 Years",{"count":214,"type":23},34,[26],"The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml\u002Fmin\u002F1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.",[29],[121,219,220],"Nephrology","eGFR","2026-07-24",{"date":223,"type":36},"2026-07-27",{"date":199,"type":23},{"date":226,"type":23},"2028-05",{"name":228,"class":75},"Centre Hospitalier Universitaire de Nice",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":250},"100452607","phase-2-sit-less-interact-and-move-more-slimm-2-study-100452607","NCT05173714","Sit Less, Interact and Move More (SLIMM) 2 Study","Inclusion Criteria:\n\n* Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \\\u003C60 mL\u002Fmin\u002F1.73m\\^2\n* Able to perform resistance training\n* Access to compatible \"smartphone\" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* History of gastroparesis or paralytic ileus\n* At baseline, if sedentary time is 25 min\u002Fhr or less, measured by accelerometer\n* Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.\n* Previous bariatric surgery\n* Medical condition likely to limit survival to less than 1 year\n* Anticipated start of dialysis or kidney transplantation within 6 months\n* Any factors judged by the investigator or study team to likely limit adherence to interventions\n* Vulnerable populations- pregnant or incarcerated\n* Enrolled in interventional trials using drugs or devices\n* Not able to undergo informed consent\n* Recent hospitalizations or major interventional procedures done within the past 60 days\n* Known or suspected hypersensitivity to tegaderm\n* Use of any GLP-1 receptor agonist within 30 days prior to screening\n* Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure\n* Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)\n* Presence of metastatic cancer\n* Current use of mobility aid(s)\n* Living in the same household of a participant already enrolled in the study","20 Years",{"count":237,"type":23},156,[239],"PHASE2","* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.\n* In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained.\n* Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2.\n* This NIH funded study is conducted at the University of Utah and Stanford University.\n* The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.",[29,93],"2026-07-23",{"date":223,"type":36},{"date":245,"type":36},"2021-12-01",{"date":247,"type":23},"2027-03-31",{"name":249,"class":75},"Srinvasan Beddhu",2,{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":250},"100578386","navigate-kidney-a-multi-level-intervention-to-reduce-kidney-health-disparities-100578386","NCT06810622","NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities","Navigate Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities Among Individuals With Kidney Disease","NAV-Kidney","Inclusion Criteria:\n\n* Adults ≥ 18 years of age,\n* Adults who are not pregnant,\n* Adults who are not incarcerated,\n* Adults who have advanced kidney disease with an eGFR of 15-29 mL\u002Fmin\u002F1.73m2). No other measures are used to identify eligible patients.\n\nExclusion Criteria:\n\n* Previous kidney transplant\n* Previous surgery for dialysis such as an arteriovenous fistula, arteriovenous graft, or peritoneal dialysis catheter placement\n* On chronic dialysis\n* Conservative management or primary goal is palliation\n* Incarcerated\n* Pregnant\\*\n* Under 18 years of age\n* Moderate to severe dementia\n* Deaf persons\n* Lacking health insurance\\*\\*\n* Investigator Discretion: Individuals who, in the judgment of the Site PI (or designee), are deemed unsuitable for participation due to behavioral or logistical circumstances that could compromise study integrity or the safety of the participant or staff.","75 Years",{"count":261,"type":23},448,[88],"The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD. The project will have four (4) aims.",[122,29],[266,267,268,269],"Kidney","Chronic","Dialysis","Transplant","2026-07-22",{"date":221,"type":36},{"date":273,"type":36},"2026-03-18",{"date":275,"type":23},"2029-05-15",{"name":277,"class":75},"University of Colorado, Denver",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":286,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":44},"100572832","enhancing-physical-function-in-older-adults-with-chronic-kidney-disease-100572832","NCT06738394","Enhancing Physical Function in Older Adults With Chronic Kidney Disease","Enhancing Physical Function in Older Adults With Chronic Kidney Disease (EPIC): A Pilot Randomized Controlled Trial","EPIC","Inclusion Criteria:\n\n* Chronic kidney disease stages 3-5\n* Capacity to complete physical exercise\n* Lives within 20 miles of Wake Forest Reynolda Campus\n* Fluent English speaker\n* Does not plan to travel outside of home area for an extended period of time during study\n* Willing to be randomized to either intervention group\n\nExclusion Criteria:\n\n* Receiving renal replacement therapy (e.g. hemodialysis, peritoneal dialysis) or anticipated to start renal replacement therapy in the next 6 months\n* Dependent on a wheelchair\n* Current participation in a resistance training program\n* Joint replacement or orthopedic surgery in the previous 6 months or planning to have surgery in the next 6 months months\n* Absolute contraindications to exercise testing according to ACSM:\n\nAcute myocardial infarction within the past 6 months Ongoing unstable angina Uncontrolled cardiac arrhythmia with hemodynamic compromise Active endocarditis Symptomatic severe aortic stenosis Decompensated heart failure Acute pulmonary embolism, pulmonary infarction, or deep venous thrombosis Acute myocarditis or pericarditis Acute aortic dissection\n\n* Parkinson's disease\n* Respiratory disease requiring oxygen\n* Cancer requiring treatment\n* Currently receiving physical therapy or cardiopulmonary rehabilitation\n* Type I or insulin dependent Type II Diabetes\n* Scoring below 32 points on the Telephone Interview for Cognitive Status (TICS)\n* Site PI\u002FStudy Clinician discretion regarding medical status, appropriateness of participation or concern about intervention adherence","65 Years","100 Years",{"count":289,"type":23},30,[88],"The goal of this pilot randomized controlled trial is to examine the feasibility and safety of a 12-week high-velocity resistance training (HVRT) intervention in older adults with chronic kidney disease (CKD) stages 4-5 and to generate preliminary data to inform a future study investigating the efficacy of HVRT for improving muscle power and physical function. Researchers will compare HVRT to an attention control condition consisting of weekly group sessions covering topics on healthy lifestyle. This study seeks to:\n\n1. Determine whether implementing an HVRT intervention is feasible and safe for mobility-limited older adults with advanced CKD.\n2. Collect preliminary data on the efficacy of HVRT for improving muscle power and physical function in mobility-limited older adults with advanced CKD.",[29],[294,295,296],"kidney disease","resistance training","older adults",{"date":221,"type":36},{"date":299,"type":36},"2025-07-31",{"date":301,"type":23},"2027-07",{"name":303,"class":75},"Wake Forest University Health Sciences",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":24,"phases":314,"briefSummary":315,"conditions":316,"keywords":319,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100645654","4-7-8-breathing-for-fatigue-and-sleep-management-in-hemodialysis-100645654","NCT07700693","4-7-8 Breathing for Fatigue and Sleep Management in Hemodialysis","The Effect of the 4-7-8 Breathing Exercise Program on the Management of Fatigue and Sleep Disorders in Hemodialysis Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 85 years\n* Receiving hemodialysis treatment for at least 3 months\n* No diagnosis of malignant respiratory disease (e.g., bronchial or lung cancer)\n* No pathological condition affecting consciousness or focus (e.g., dialysis dementia or uremic encephalopathy)\n* Native Turkish speaker\n\nExclusion Criteria:\n\n* Advanced reading comprehension problems\n* Advanced hearing impairment\n* Presence of sleep apnea\n* Known psychiatric illness.","85 Years",{"count":313,"type":23},80,[88],"For many hemodialysis patients, fatigue and sleep disturbances are common and debilitating side effects that severely impact daily life and quality of life. In this study, patients will be taught a simple breathing exercise called the 4-7-8 technique to help manage these symptoms. A total of 80 adult patients undergoing regular hemodialysis at Izmir Atatürk Training and Research Hospital will be randomly assigned to two groups: an intervention group and a control group. Participants in the intervention group will receive a face-to-face training session from a research nurse and a short instructional video sent to their smartphones to encourage daily home practice, especially before bedtime. The program will be continued over the study period. Participants in the control group will continue with their current routine hemodialysis care without any structured breathing exercises. Fatigue levels, sleep quality, and daytime sleepiness will be measured in both groups before and after the program using validated questionnaires. The results of this study may provide nurses and patients with a safe, cost-effective, non-drug option to improve symptom management and overall well-being in hemodialysis patients.",[29,317,318],"Insomnia","4-7-8 Breathing Technique",[318,320,151,321],"Non-pharmacological Pain Management","insomnia","2026-07-14",{"date":324,"type":36},"2026-07-15",{"date":326,"type":23},"2026-08-01",{"date":328,"type":23},"2027-01-30",{"name":330,"class":75},"Izmir Kavram Vocational School",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":311,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":4},"100645450","effect-of-4-7-8-breathing-on-av-fistula-needle-pain-in-dialysis-patients-100645450","NCT07700680","Effect of 4-7-8 Breathing on AV Fistula Needle Pain in Dialysis Patients","The Effect of a 4-7-8 Breathing Exercise Program on the Management of Arteriovenous Fistula Intervention Pain in Hemodialysis Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Being 18-85 years of age or older\n\n  * Receiving HD treatment 3 days a week\n  * Being able to read and write\n  * Having no hearing impairment\n  * Having Turkish as their native language\n  * Having received HD treatment for at least 6 months\n  * Having a VAS pain score \\>3\n  * Agreeing to listen to music\n\nExclusion Criteria:\n\n* Having a psychological disorder\n\n  * Having communication problems\n  * Having cancer\n  * Not wanting to participate in the study",{"count":313,"type":23},[88],"For many hemodialysis patients, needle insertion into the vascular access site (fistula) is a significant source of pain and anxiety. In this study, patients will be guided to perform breathing exercises using the 4-7-8 breathing technique during needle insertion to reduce this pain. A total of 80 adult patients undergoing regular hemodialysis at Izmir Atatürk Training and Research Hospital will be randomly assigned to two groups: an intervention group and a control group. Participants in the intervention group will be taught a standardized intervention program consisting solely of the 4-7-8 breathing technique, to be applied before and during AVF cannulation. The program will be implemented during every hemodialysis session (three times a week) for one week. The technique will be explained in person by a research nurse before the first session, and patients will be provided with a short instructional video demonstrating the technique step by step. The video will be sent to patients' smartphones to encourage them to practice at home. Participants in the control group, however, will continue with their current routine hemodialysis care and standard cannulation procedures (without any structured breathing exercises). The results of this study may provide nurses and patients with easy-to-use, evidence-based options to make hemodialysis needle procedures less painful and stressful.",[29,342,343],"Pain, Procedural","Arteriovenous Fistula",[320,151,345,346,318],"Vascular Access","Cannulation Pain",{"date":324,"type":36},{"date":349,"type":23},"2026-07-20",{"date":328,"type":23},{"name":330,"class":75},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":83,"sex":18,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":44},"100520015","care-transitions-app-for-patients-with-multiple-chronic-conditions-100520015","NCT06051058","Care Transitions App for Patients With Multiple Chronic Conditions","Inclusion Criteria:\n\n* Adult patients (55+) with a Brigham PCP or appointment in one of the 15 locations discharging from a BWH general medicine unit\n* Discharging to home, home health care service or assisted living\n* Fluent in spoken English in patient or healthcare proxy\n* Patients with at least one of the conditions listed below + one additional chronic condition on the problem list.\n* Patient with heart failure on the problem list\n* Patient with type 2 diabetes on the problem list\n* Patient with chronic kidney disease on the problem list\n\nExclusion Criteria:\n\n* Adult patients (55+) with Westwood, Pembroke, or Transition Clinic PCP admitted to ICU, OBGYN, Surgical, Cardiology, Oncology, Orthopedics, or other Specialty Unit\n* Pregnant\n* Prisoner, institutionalized individual or in police custody\n* Discharge planned within 3 hours of screening\n* Patient too ill to participate or with active psychosis\u002Fserious mental illness, delirium, or severe dementia\n* Not fluent in spoken English in patient and health proxy\n* Unlikely to be discharged to home\n* Lacks a device capable of accessing the app\n* Lack of a working telephone for 30-day follow-up","55 Years",{"count":360,"type":23},798,[88],"The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.",[364,365,92,366,29],"Heart Failure","Congestive Heart Failure","Diabetes Mellitus","2026-07-08",{"date":369,"type":36},"2026-07-09",{"date":371,"type":36},"2024-10-08",{"date":373,"type":23},"2027-12",{"name":375,"class":75},"Brigham and Women's Hospital",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":250},"100360929","protecting-kidneys-through-a-low-protein-diet-a-stepwise-multiple-choice-system-approach-100360929","NCT03979534","Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach","ProReRePro","Inclusion Criteria:\n\n* All adult patients followed on the unit for advanced CKD, with Kidney disease stage 4-5 or stage 3 with fast progression and without contraindications.\n\nExclusion Criteria:\n\n* Malnutrition or short life-expectancy\n* Patients aged less than 18 years old\n* Pregnant women,\n* Incapacity to complete the free-consent form,\n* Pateints refusing participation in the study,\n* Patients without healthcare coverage.",{"count":384,"type":23},100,[88],"Nephrology care continues to progress and recommendations are now focused on delaying as much as possible the need for renal replacement therapy (\"intent-to-defer\"strategy). Protein restriction is a valuable tool for stabilizing chronic kidney disease (CKD) and retarding the need for renal replacement therapy, but the best diet to be prescribed is still matter of discussion. This study is aimed at identifying implementation strategies for nutritional management of advanced CKD.",[29],[389,390,391,392,393,394],"low-protein diet","pre-dialysis","chronic kidney disease","nutritional care","start of dialysis","incremental dialysis","2026-06-30",{"date":397,"type":36},"2026-07-01",{"date":399,"type":36},"2019-04-01",{"date":401,"type":23},"2028-04-01",{"name":403,"class":75},"Centre Hospitalier le Mans",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":428},"100601857","streamlined-denervation-with-spyral-for-an-optimized-treatment-spyral-swyft-in-subjects-with-uncontrolled-hypertension-100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%",{"count":413,"type":23},130,[88],"The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[417,418,419,29,366],"Hypertension","Vascular Diseases","Cardiovascular Diseases","2026-06-29",{"date":395,"type":36},{"date":423,"type":36},"2025-09-22",{"date":425,"type":23},"2029-12-31",{"name":427,"class":161},"Medtronic Vascular",21,{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":212,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":458},"100585805","spyral-gemini-pilot-study-100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.",{"count":438,"type":23},175,[88],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[417,418,419,29,366],[443,444,445,446,122,417,419,418,447,448,449],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Denervation","Renal Denervation","Hepatic Denervation","2026-06-22",{"date":452,"type":36},"2026-06-24",{"date":454,"type":36},"2025-05-01",{"date":456,"type":23},"2029-12-22",{"name":427,"class":161},18,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":83,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":44},"100552521","assessment-of-t-cell-response-and-in-vitro-proof-of-concept-of-t-cell-engineering-in-chronic-eskd-patients-100552521","NCT06474169","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.","LYMPHOVIR-IRCT","Inclusion Criteria:\n\n1. Male or female ≥ 18 years\n2. Informed participants who did not object to participating in the study\n\nExclusion Criteria:\n\n1. Chronic progressive infections\n2. Prior organ transplantation (including bone marrow transplantation)\n3. Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion\n4. Participant under guardianship, curatorship or deprived of liberty\n5. Pregnant or breastfeeding women",{"count":384,"type":23},"This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.\n\nThe study population was patients with chronic kidney disease.",[29],[471,472,473,474],"end-stage kidney disease","T-cells response","Immunodeficiency","Proof of concept of T-cell therapy",{"date":476,"type":36},"2026-06-25",{"date":478,"type":36},"2024-11-27",{"date":480,"type":23},"2026-12",{"name":482,"class":75},"Centre Hospitalier Régional d'Orléans",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":497,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":506,"leadSponsor":508,"locationsCount":510},"100643970","phase-4-finerenone-for-regression-of-albuminuria-in-type-2-diabetes-with-chronic-kidney-disease-100643970","NCT07667517","Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease","Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","Inclusion Criteria:\n\n* 1\\. Age \\>= 18 years at the time of signing informed consent, male or female.\n* 2\\. Type 2 diabetes mellitus.\n* 3\\. Chronic kidney disease meeting BOTH of the following: eGFR (CKD-EPI) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2, and UACR 30-2000 mg\u002Fg (mean of 3 measurements).\n* 4\\. Serum potassium \\\u003C= 5.0 mmol\u002FL.\n* 5\\. On a maximum tolerated dose of an ACE inhibitor or ARB for at least 90 days.\n* 6\\. Treatment with an SGLT-2 inhibitor, GLP-1 receptor agonist, or other agents affecting UACR is permitted, but the type and dose must be stable for at least 30 days before screening.\n\nExclusion Criteria:\n\n* 1\\. Type 1 diabetes, other specific types of diabetes, or gestational diabetes.\n* 2\\. HbA1c \\>= 8.0%.\n* 3\\. On renal replacement therapy.\n* 4\\. Acute kidney injury within 180 days before the screening visit.\n* 5\\. Hepatic impairment (Child-Pugh class C).\n* 6\\. Blood pressure \\> 160\u002F100 mmHg, or systolic blood pressure \\\u003C 90 mmHg, at the screening visit.\n* 7\\. Bilateral renal artery stenosis.\n* 8\\. Known hypersensitivity to the study drug (active substance or excipients).\n* 9\\. Treatment with finerenone within 60 days before screening.\n* 10\\. Stroke, transient ischemic attack, acute coronary syndrome (myocardial infarction, CABG, PCI), or hospitalization for worsening heart failure within 90 days before the screening visit.\n* 11\\. NYHA class II-IV heart failure.\n* 12\\. Addison's disease.\n* 13\\. Gastrointestinal surgery that may affect drug absorption.\n* 14\\. Any other history, condition, therapy, or uncontrolled concomitant disease that makes the participant unsuitable for the study or unlikely to complete it (e.g., active malignancy or other disease with life expectancy \\\u003C 12 months).\n* 15\\. Treatment with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin, nefazodone), a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort), or a moderate CYP3A4 inducer (e.g., efavirenz) that cannot be discontinued for at least 7 days before randomization.\n* 16\\. Treatment with another mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone, esaxerenone) or a potassium-sparing diuretic (e.g., amiloride, triamterene) that cannot be discontinued for at least 60 days before the screening visit.\n* 17\\. Biopsy-confirmed non-diabetic kidney disease (e.g., IgA nephropathy).\n* 18\\. Immunosuppressive therapy, or glucocorticoid use by any route other than topical or inhaled, within the past 180 days.\n* 19\\. Participation in another interventional clinical study or use of any investigational product within 90 days before randomization.\n* 20\\. History of alcohol or drug abuse.\n* 21\\. Women of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using adequate contraception during the study.\n* 22\\. Any other condition deemed by the investigator to make the participant unsuitable for the study.",{"count":491,"type":23},148,[26],"This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 and UACR 30-2000 mg\u002Fg) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (\\\u003C300 vs \\>=300 mg\u002Fg), to oral finerenone (10 or 20 mg once daily, titrated by serum potassium and eGFR) or matching placebo, on top of standard background therapy, for 180 days, followed by a 30-day off-treatment follow-up. Albuminuria regression is defined as both an improvement in Kidney Disease: Improving Global Outcomes albuminuria category, from A3 to A2 or A1, or from A2 to A1, and a more than 30% reduction in urinary albumin-to-creatinine ratio from baseline. The outcome will be reported as the percentage of participants meeting this definition at Day 180.",[495,496,29],"Albuminuria","Type 2 Diabetes Mellitus (T2DM)",[498,499,500,501,502],"Finerenone","Nonsteroidal mineralocorticoid receptor antagonist","Urine albumin-to-creatinine ratio","KDIGO","Albuminuria regression","2026-06-19",{"date":476,"type":36},{"date":397,"type":23},{"date":507,"type":23},"2027-12-31",{"name":509,"class":75},"First Affiliated Hospital of Zhejiang University",13,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":519,"conditions":520,"keywords":525,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":44},"100506940","precision-medicine-approaches-to-renal-osteodystrophy-100506940","NCT05880914","Precision Medicine Approaches to Renal Osteodystrophy","PMaROD","Inclusion Criteria:\n\n1. Study participant has provided informed consent\n2. Age ≥ 18 years\n3. CKD Stages 3-5D regardless of kidney transplantation status\n4. CKD5D patients receiving maintenance hemodialysis for at least 3 months\n5. Clinically indicated treatment for renal hyperparathyroidism, renal osteodystrophy and\u002For Osteoporosis\n6. PTH, BSAP and CTX meets defined thresholds for low or high turnover ROD type or a Bone biopsy evidence of low or high turnover based\n\nExclusion Criteria:\n\n1. Currently receiving treatment in an investigational device or drug study, or less than 30 days since ending treatment on an investigational device or drug study(s)\n2. Currently receiving investigational procedures\u002Fdrugs from another study while participating in this study\n3. Use of etelcalcetide, bisphosphonate, denosumab, teriparatide, abaloparatide or romosozumab during the 6 months prior to study enrollment; however, participant can be included if being treated with bone active agent but will have class change to an agent that will result in a change in bone turnover from low to high or high to low\n4. New use of cinacalcet over the prior 6 months\n5. Use of Zoledronic Acid (Reclast) less than 24 months from study enrollment for patients with eGFR \\\u003C30mL\u002Fminute\n6. Anticipated or scheduled kidney transplant during the study period or less than 1 year from receiving a kidney transplant\n7. For patients with a solid organ transplant, less than 1 year from receiving the transplant\n8. Patient has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator\n9. Metabolic bone diseases not related to the kidney (e.g., Paget's, Osteogenesis Imperfecta)\n10. Endocrinopathy (e.g., untreated hyperthyroidism)\n11. Malignancy within the last 5 years (except non-melanoma skin cancers or cervical carcinoma in situ)\n12. Patient is pregnant or nursing\n13. Weight \\>300 pounds (scanner limitation)\n14. Allergy to tetracycline or demeclocycline\n15. Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy\n16. Patient unable to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures to the best of the patient and Investigator's knowledge",{"count":55,"type":23},"Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasive biomarker of turnover for renal osteodystrophy.",[521,29,522,523,524],"Renal Osteodystrophy","CKD-MBD","Bone Turnover Rate Disorder","Secondary Hyperparathyroidism",[526,527,528,529,530],"Bone biopsy","microRNA","HR-pQCT","Bone biomarkers","Bone imaging","2026-06-11",{"date":533,"type":36},"2026-06-12",{"date":535,"type":36},"2022-12-21",{"date":537,"type":23},"2027-06-30",{"name":539,"class":75},"Thomas Nickolas",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":84,"enrollmentInfo":547,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100561686","phase-2-safety-and-tolerability-of-difelikefalin-in-adolescents-on-haemodialysis-with-moderate-to-severe-pruritus-100561686","NCT06593392","Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus","Inclusion Criteria:\n\n* 1\\. Participant must be ≥12 to \\\u003C18 years of age at the time of informed consent.\n* 2\\. Participants with CKD on HD 3 times weekly for at least 12 weeks prior to the informed consent procedure who can continue HD without changing its frequency or method.\n* 3\\. Participants whose WI-NRS score in the 7-day run-in period (meets both of the below:\n* a) WI-NRS scores have been recorded for at least 4 days through a 7-day run-in period.\n* b) The mean value of the recorded WI-NRS scores is \\>4.0\n* 4\\. Over the last 3 months prior to screening, the participant has had at least 1 of the following:\n* a) At least 2 single-pool Kt\u002FV measurements ≥1.2 on different dialysis days\n* b) At least 2 urea reduction ratio measurements ≥65% on different dialysis days\n* c) 1 single-pool Kt\u002FV measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis day\n* 5\\. Prescription dry body weight ≥20 kg\n* 6\\. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* 7\\. Participant and\u002For legal guardian (as required) is capable of providing the appropriate signed informed consent and where appropriate, assent.\n\nExclusion Criteria:\n\n* 1\\. Known to be non-compliant with HD treatments and deemed unlikely by the Investigator to complete the study\n* 2\\. Planned to receive a kidney transplant during the study. Note: being listed on a kidney transplant list is not an exclusion criterion.\n* 3\\. Participants with itching caused by conditions other than chronic renal failure or complications of chronic renal failure, which could in the opinion of the Investigator affect the efficacy evaluation (e.g., atopic dermatitis, chronic urticaria).\n* 4\\. Participants with localised itch restricted to the palms of the hands.\n* 5\\. Participants with pruritus only during the dialysis session (by participant report).\n* 6\\. Participants with known concurrent hepatic cirrhosis or severe hepatic impairment (e.g., Child-Pugh Class C).\n* 7\\. Significant systolic or diastolic heart failure (e.g., New York Heart Association Class IV congestive heart failure).\n* 8\\. Participants with concurrent malignancy except excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ that has been excised or resected completely.\n* 9\\. Severe mental illness or cognitive impairment (e.g., dementia) or other concurrent mental disorder that, in the opinion of the Investigator, would compromise the validity of study measurements.\n* 10\\. Conditions associated with clinically important disruptions to the blood brain barrier (for example, primary brain malignancies, CNS metastases or other inflammatory conditions, active multiple sclerosis, advanced Alzheimer's disease) that in the Investigator's opinion may be associated with unacceptable risk for CNS effects.\n* 11\\. Acute or unstable medical condition(s) that in the Investigator's opinion, may be associated with increased risk to the participant, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures.\n* 12\\. Participant is receiving ongoing ultraviolet B treatment and anticipates receiving such treatment during the study.\n* 13\\. New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening.\n* 14\\. New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening.\n* 15\\. Participant is receiving prohibited medication (e.g., nalfurafine hydrochloride, opioid antagonists) that cannot be stopped at least 14 days before enrolment in the study.\n* 16\\. Participant has known hypersensitivity to the study intervention or any components of the difelikefalin formulation.\n* 17\\. Known or suspected history of alcohol, narcotic, or other drug abuse or substance dependence within 12 months prior to screening or participant with any alcoholic beverage intake of more than two units per day more than once per week.\n* 18\\. Participation in any other investigational device or drug study \\\u003C30 days prior to screening, or current treatment with other investigational agent(s).\n* 19\\. Serum ALT, AST greater than 3× the reference ULN.",{"count":458,"type":23},[239],"Rationale:\n\n* People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.\n* Difelikefalin is a medicine that can treat the itching related to long term kidney disease.\n* Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable.\n* The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is safe in this age group.\n\nThe aims of the study are:\n\nMain aim: To assess the safety of difelikefalin in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nSecondary aim: To measure the amount of difelikefalin that enters the blood in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nStudy Design At least 18 adolescents, aged 12 to 17 years, who are on haemodialysis and have itching related to long term kidney disease will take part in this study.\n\nAll study participants will receive difelikefalin 3 (or up to 4) times weekly for up to 12 weeks. The study duration for a participant is up to 17 to 18 weeks; during this period, participants will visit the clinic 3 times weekly (during their haemodialysis visits).",[551,29],"Pruritus",[553],"Chronic kidney disease associated pruritus","2026-06-10",{"date":531,"type":36},{"date":557,"type":23},"2026-06-17",{"date":559,"type":23},"2029-08-15",{"name":561,"class":161},"Vifor Fresenius Medical Care Renal Pharma",16,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":83,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":572,"briefSummary":573,"conditions":574,"keywords":576,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":44},"100571091","theory-based-health-behaviour-change-intervention-in-individuals-of-metabolic-syndrome-with-chronic-kidney-disease-100571091","NCT06715735","Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of A Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension), and CKD;\n* Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who have medical contraindications to exercise, including walking;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":571,"type":23},160,[88],"This study will adopt a 2-arm, pretest-posttest, and assessor-blind RCT design to examine the effectiveness of a theory-based health behaviour change intervention on WC (primary outcome), kidney function (eGFR, primary outcome), dietary behaviour, PA, exercise capacity, and self-efficacy of dietary behaviour and PA among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nA total of 160 adults with metabolic syndrome and chronic kidney disease will be recruited, with 80 participants in each group. Data will be collected at 3-time points (baseline, immediate post-intervention and 1-month post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[29,575],"Metabolic Syndrome",[575,121,577,578,579,580],"Waist Circumference","Kidney Function","Behaviour Change Intervention","Health Action Process Approach","2026-06-09",{"date":531,"type":36},{"date":584,"type":36},"2024-12-20",{"date":586,"type":23},"2026-10-30",{"name":588,"class":75},"Chinese University of Hong Kong",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":83,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":44},"100556643","theory-based-health-behaviour-change-intervention-in-patients-of-metabolic-syndrome-with-chronic-kidney-disease-100556643","NCT06527768","Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of a Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension) and CKD;\n* No medical contraindications to exercise, including walking;\n* Participants are capable of understanding and providing informed consent;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese;\n* Stay in Chengdu during the study period.\n\nExclusion Criteria:\n\n* Participants who cannot perform brisk walking exercise;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Participants who have a cognitive impairment, which will be screened by the abbreviated mental test with a score lower than seven;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":55,"type":23},[88],"The pilot study will adopt a 2-arm, pretest-posttest, and assessor-blind randomized controlled trial design to examine the feasibility and acceptability of a theory-based health behaviour change intervention and examine its effects on waist circumference (primary outcome), kidney function (estimated glomerular filtration rate, urine albumin-to-creatinine ratio, primary outcome), dietary behaviour, physical activity, exercise capacity and self-efficacy of diet behaviour and physical activity among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nResearchers will compare the theory-based health behaviour change intervention to usual care to see if the theory-based health behaviour change intervention can reduce waist circumference and preserve kidney function over three months.\n\nA total of 40 adults with metabolic syndrome and chronic kidney disease will be recruited, with 20 participants in each group. Data will be collected at two-time points (baseline and immediate post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[29,575],[575,121,577,578,579],{"date":531,"type":36},{"date":603,"type":36},"2024-07-31",{"date":605,"type":23},"2026-07-31",{"name":588,"class":75},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":614,"maxAge":311,"enrollmentInfo":615,"targetDuration":4,"studyType":24,"phases":617,"briefSummary":618,"conditions":619,"keywords":620,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":628,"locationsCount":44},"100600239","handgrip-exercise-training-and-ckd-100600239","NCT07094906","Handgrip Exercise Training and CKD","Neural and Vascular Modulation With Isometric Handgrip Training in Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients with CKD (Stages IIIa and IV),\n* Ages 45-85 years who do not regularly exercise (defined as exercising less than 20 minutes twice per week), willing and able to cooperate with the protocol.\n* CKD Stages III and IV will be defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc\u002Fminute as calculated by the modified CKD-EPI equations.\n* Patients with CKD must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months).\n\nExclusion Criteria:\n\n* Severe CKD (eGFR\\\u003C15 cc\u002Fminute)\n* Metabolic alkalosis (serum bicarbonate \\> 28 meq\u002FL)\n* Ongoing drug or alcohol abuse\n* Diabetic neuropathy\n* Any serious systemic disease that might influence survival\n* Severe anemia with hgb level \\\u003C10 g\u002FdL\n* Clinical evidence of congestive heart failure or ejection fraction below 35%, symptomatic heart disease determined by prior electrocardiogram, stress test, and\u002For history, treatment with central alpha agonists (clonidine)\n* Uncontrolled hypertension with BP greater than 170\u002F100 mm Hg\n* Low blood pressure with BP less than 100\u002F50\n* Pregnancy or plans to become pregnant\n* Current treatment with MAO inhibitors\n* Inability to perform handgrip exercise","45 Years",{"count":616,"type":23},50,[88],"The purpose of this study is to find out if regular handgrip exercise performed at home can improve blood pressure at rest and during exercise in patients with chronic kidney disease (CKD).\n\nThis study is also intended to understand what causes an increase in blood pressure at rest and during exercise (i.e., increased adrenaline levels, or decreased ability of blood vessels to dilate). Patients with CKD will be recruited from primary care, Nephrology and other subspecialty Clinics throughout the Emory Healthcare System. Participants will attend 4 visits of 2-3 hours and 3 visits of 1-2 hours. The home exercise training will last for 8 weeks.",[29],[621,622,623],"Handgrip","Isometric handgrip exercise training (IHT)","Blood pressure variability","2026-06-08",{"date":554,"type":36},{"date":199,"type":23},{"date":373,"type":23},{"name":629,"class":75},"Emory University",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":638,"enrollmentInfo":639,"targetDuration":4,"studyType":24,"phases":641,"briefSummary":642,"conditions":643,"keywords":646,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":44},"100638389","effectiveness-of-health-literacy-program-for-polypharmacy-patients-hlp-ckd-100638389","NCT07622134","Effectiveness of Health Literacy Program for Polypharmacy Patients (HLP-CKD)","Effectiveness of the Health Literacy Promotion Program to Prevent Chronic Kidney Disease of Patients Who Use Polypharmacy","HLP-CKD","Inclusion Criteria:\n\n* Patients aged 55-74 years diagnosed with non-communicable diseases.\n* Currently taking 5 or more medications daily (Polypharmacy) for at least 6 months.\n* Have at least one risk factor for chronic kidney disease (e.g., Hypertension or Diabetes).\n* Able to communicate, read, and write in Thai.\n* Willing to participate in the 8-week program and follow-up assessments.\n\nExclusion Criteria:\n\n* Patients already diagnosed with Chronic Kidney Disease (CKD) stage 3 - 5.\n* Having severe cognitive impairment or psychiatric disorders that prevent participation.\n* Having severe complications or being in an unstable clinical condition.\n* Planning to move out of the study area during the 12-week study period.","74 Years",{"count":640,"type":23},104,[88],"This study aims to evaluate the effectiveness of a health literacy promotion program in preventing chronic kidney disease (CKD) among patients who use multiple medications (polypharmacy). Participants will be divided into two groups: an experimental group receiving the health literacy program and a control group receiving standard care. The study will measure improvements in health literacy levels and CKD prevention behaviors over a specific period. It is expected that the program will help patients better manage their medications and reduce the risk of developing kidney complications.",[29,644,645],"Polypharmacy","Health Literacy",[647,648,649,650,651,652],"Health Literacy Program","CKD Prevention","Medication Management","Nursing Intervention","Randomized Controlled Trial","Thailand","2026-06-03",{"date":655,"type":36},"2026-06-04",{"date":657,"type":23},"2026-06-15",{"date":659,"type":23},"2026-11-15",{"name":661,"class":75},"Nakhon Pathom Rajabhat University"]